CHD Bioscience is a multi-product development-stage healthcare company that has created a technology platform to stem the rising tide of drug-resistant pathogens by creating unique topical therapeutics for unmet medical needs in the dermal and orthopedic markets. CHD technology is focused on serious, unmet medical needs in the following markets: Wound Care (wound dressings and bandages, wound gels, wound washes and instillation products and coated internal surgical meshes), Orthopedics (orthopedic coatings, orthopedic flushing solutions) and Therapeutic Topical Soft Tissue Infections (Topical products for skin and structural skin infections). CHD's first generation agent, VERIOX, is a novel, anti-microbial agent with demonstrated unique safety and efficacy properties which can mitigate the increasing threat of pathogens such as MRSA, CRE, VRE and C. difficile spores.